The body contains a specialized system call the endocannabinoid system. It’s a signaling system associated with emotional responses, sleep regulation, appetite, pain and immune system response.1,3 It is possible that plant-derived cannaboids, like CBD, could stimulate the actions of this system.  Studies into the efficacy of CBD oil in humans are in their infancy, but many animal studies support its potential benefits.

Several studies demonstrate the ability of CDB to reduce behaviors in animals that have been associated with mood problems in humans.  While more research is needed, studies with humans support these findings.1 Animal studies also indicate that CBD oil can have mood elevating effects.2 Preliminary studies also suggest that CBD can help with insomnia and excessive daytime sleepiness.3

While more clinical studies are needed, anecdotal evidence supports the potential benefits of CBD. For example, a large survey designed to assess interest in CBD found that of almost 1,500 people who had been using CBD to manage symptoms of medical conditions like pain and mood problems, more than a third said CBD worked “very well by itself.”4 Research also suggests that CBD may impact the endocannabinoid system in reducing generalized swelling.5

In addition to research being conducted in this area, the FDA has approved a CBD-based medication for treatment of seizures in two rare forms of epilepsy.6

Citations

1. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a Potential Treatment
for Anxiety Disorders. Neurotherapeutics 2015;12:825-36.
2. Pandini Silote G, Sartim A, Sales A, et al. Emerging Evidence for the Antidepressant Effect of
Cannabidiol and the Underlying Molecular Mechanisms. J Chem Neuroanat 2019;98:104-16.
3. Babson KA, Sottile J, Morabito D. Cannabis, Cannabinoids and Sleep: A Review of the Literature.
Curr Psychiatry Rep 2017;19(4):23-34.
4. Corroon J, Phillips JA. A Cross-Sectional Study of Cannabidiol Users. Cannabis Cannabinoid Res.
2018;3(1):152-161.
5. Darkovska-Serafimovska M, et al. Pharmacotherapeutic Considerations For Use Of Cannabinoids
To Relieve Pain In Patients With Malignant Diseases. J Pain Res 2018:11:837-42.
6. U.S Food & Drug Administration. FDA Approves First Drug Comprised of an Active Ingredient
Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy. https://www.fda.gov/news-
events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-
marijuana-treat-rare-severe-forms Accessed June 1, 2019.